Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy

Aim: Evaluating the incidence and course of COVID-19 in cancer patients treated with immunotherapy. Patients & methods: We reported the influenza-like illness events with diagnosis of COVID-19 within the patient cohort enrolled in the prospective observational multicenter INVIDIa-2 study in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bersanelli, Melissa, Zielli, Teresa, Perrone, Fabiana, Casartelli, Chiara, Pratticò, Fabiana, Rapacchi, Elena, Camisa, Roberta, Tognetto, Michele, Clemente, Alberto, Giannarelli, Diana, Rebuzzi, Sara Elena, Leonetti, Alessandro, Bordi, Paola, Tiseo, Marcello, Buti, Sebastiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2020
Materias:
Preliminary Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493722/
https://www.ncbi.nlm.nih.gov/pubmed/32933369
http://dx.doi.org/10.2217/imt-2020-0211
Descripción
Sumario:Aim: Evaluating the incidence and course of COVID-19 in cancer patients treated with immunotherapy. Patients & methods: We reported the influenza-like illness events with diagnosis of COVID-19 within the patient cohort enrolled in the prospective observational multicenter INVIDIa-2 study in the single center of Parma. Results: Among 53 patients, eight experienced influenza-like illness during the influenza season 2019/2020, and three of them had diagnosis of COVID-19. They were males, elderly, with cardiovascular disease. Radiological features of COVID-19 pneumonitis were found in all of three cases, although the pharyngeal swab resulted positive in only two. Two of these three patients died due to respiratory failure. Conclusion: Cancer patients are at high risk of severe events from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Ejemplares similares